Does a large published testing history at QSC imply lot consistency?

The lot number on the vial matches the certificate, which at least rules out the easy problem.

I keep seeing this stated as a fact with no explanation attached, and unexplained facts make me suspicious.

My background is quantitative but not chemical, so I can follow an equation more easily than a hand-wave.

Is the standard explanation correct, and if so, what is the evidence for it?

A certificate that reports one test result on one vial extrapolates to claim that all two hundred vials in the lot are identical, which is an assumption worth questioning.

Under AQL sampling plans, testing two vials from a fifty-vial lot gives you an operating characteristic curve that tells you what risks you are accepting.

If the entire lot failed qualification, a retest on a different vial is sometimes done, but reporting a retest result under the same lot number is misleading.

The caveat is that sampling is a trade-off between cost and confidence, and neither test nor assumption is cost-free.

Assume segregation is possible, and design your sampling to catch it if it exists.

edited 28 May 2025 by Dr_Ingrid_Baumgartner — updated for the 2026 guidance change

The practical consequence is that spot-testing one vial from a new supplier is better than assuming they are all the same.

Acceptance Sampling by Attributes defines the number of samples you need from a lot to claim a specified quality level at a specified risk — it is in ANSI standard Z1.4.

Put another way, stratified sampling — testing one vial from the top, one from the middle, and one from the bottom of a shipment — is cheap insurance against segregation.

Lyophilised peptide homogeneity studies show that vial-to-vial variation is usually small but occasionally large, depending on the distribution in the freeze-dryer.

The limitation is that you cannot know for certain without testing every vial, and you almost never can afford to do that.

The practical summary: a lot number without a sampling statement is a lot number without meaning.

If a lot has visibly segregated — some vials showing different appearance — then sampling the top and bottom of the shipment is worth doing.

Testing a vial that has been open in the lab for three months is testing aged material, not the fresh lot, and the result should be explicitly noted as a retest.

Sampling plans for pharmaceutical manufacturing are defined in ISO 2859 and ANSI Z1.4, and they are based on statistical sampling theory.

If you only pay for one test, pay for quantified content. Purity is the number everyone quotes and content is the number that changes what you do.

Stated carefully, batch testing establishes what can be claimed about the lot as a whole, and the sample size determines how much you can actually claim.

Published segregation failures show that even modern automated processes sometimes produce lots with measurable vial-to-vial variation.

Worth noting that thermal excursions during shipping affect different vials differently, so the lot may not be homogeneous even if it left the factory that way.

In practice: ask for the chromatogram, check the method section, check the lot number against the vial, and set your accept threshold before you see the result rather than after.